Manning & Napier Advisors LLC Acquires 3,278 Shares of Becton, Dickinson and Company $BDX

Manning & Napier Advisors LLC lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 10.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,426 shares of the medical instruments supplier’s stock after buying an additional 3,278 shares during the period. Manning & Napier Advisors LLC’s holdings in Becton, Dickinson and Company were worth $5,343,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the period. Empowered Funds LLC raised its stake in Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 1,354 shares in the last quarter. United Bank lifted its position in Becton, Dickinson and Company by 23.9% during the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after purchasing an additional 993 shares during the period. Marshall Wace LLP grew its stake in Becton, Dickinson and Company by 365.1% during the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after buying an additional 25,022 shares in the last quarter. Finally, NewEdge Advisors LLC increased its holdings in Becton, Dickinson and Company by 34.7% in the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock valued at $4,048,000 after buying an additional 6,058 shares during the period. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 11,704 shares of company stock worth $1,963,618 over the last quarter. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $190.58 on Tuesday. The firm has a market cap of $52.51 billion, a PE ratio of 57.40, a price-to-earnings-growth ratio of 13.53 and a beta of 0.19. The business’s 50 day moving average price is $162.48 and its two-hundred day moving average price is $160.73. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a research report on Friday, August 7th. Barclays lifted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Finally, Royal Bank Of Canada increased their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a report on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.